Lacey, Simon F.

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 5,413

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine

CAR-T cell therapy researchChronic Lymphocytic Leukemia Research

Cited by 1,785

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine

CAR-T cell therapy researchChronic Lymphocytic Leukemia Research

Cited by 1,729

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C., Kuri-Cervantes, L., Pampena, M. B., D’Andrea, K., et al. (2020) · Science

COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research

Cited by 1,509

CRISPR-engineered T cells in patients with refractory cancer

Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science

CAR-T cell therapy researchCRISPR and Genetic Engineering

Cited by 1,478

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 1,102

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells

Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 862

B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma

Cohen, A. D., Garfall, A. L., Stadtmauer, E. A., Melenhorst, J. J., Lacey, S. F., Lancaster, E., Vogl, D. T., Weiss, B. M., Dengel, K., Nelson, A., et al. (2019) · Journal of Clinical Investigation

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 778

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Ruella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., et al. (2018) · Nature Medicine

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 659

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

Kloss, C. C., Lee, J., Zhang, A., Chen, F., Melenhorst, J. J., Lacey, S. F., Maus, M. V., Fraietta, J. A., Zhao, Y., & June, C. H. (2018) · Molecular Therapy

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 648

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

Garfall, A. L., Maus, M. V., Hwang, W.-T., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Zheng, Z., Vogl, D. T., Cohen, A. D., Weiss, B. M., et al. (2015) · New England Journal of Medicine

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 624

Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia

Fraietta, J. A., Beckwith, K. A., Patel, P. R., Ruella, M., Zheng, Z., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., McGettigan, S. E., Cook, D. R., et al. (2016) · Blood

CAR-T cell therapy researchChronic Lymphocytic Leukemia Research

Cited by 474

Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells

Ghassemi, S., Nunez-Cruz, S., O'Connor, R. S., Fraietta, J. A., Patel, P. R., Scholler, J., Barrett, D. M., Lundh, S. M., Davis, M. M., Bedoya, F., et al. (2018) · Cancer Immunology Research

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 312

Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

Garfall, A. L., Cohen, A. D., Susanibar-Adaniya, S. P., Hwang, W.-T., Vogl, D. T., Waxman, A. J., Lacey, S. F., Gonzalez, V. E., Fraietta, J. A., Gupta, M., et al. (2023) · Blood Cancer Discovery

CAR-T cell therapy researchMultiple Myeloma Research and Treatments

Cited by 83

Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children

Diorio, C., Shaw, P. A., Pequignot, E., Orlenko, A., Chen, F., Aplenc, R., Barrett, D. M., Bassiri, H., Behrens, E., DiNofia, A. M., et al. (2020) · Blood Advances

Sepsis Diagnosis and TreatmentCAR-T cell therapy research

Cited by 61

Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019).

Schuster, S. J., Svoboda, J., Nasta, S., Chong, E. A., Porter, D. L., Landsburg, D. J., Mato, A. R., Bhoj, V. G., Milone, M., Lacey, S. F., et al. (2016) · Journal of Clinical Oncology

CAR-T cell therapy researchT-cell and B-cell Immunology

Cited by 10

Comparing Bowtie and BWA to Align Short Reads from a RNA-Seq Experiment

Medina-Medina, N., Broka, A., Lacey, S., Lin, H., Klings, E. S., Baldwin, C. T., Steinberg, M. H., & Sebastiani, P. (2012) · Advances in Intelligent and Soft Computing

Genomics and Phylogenetic StudiesAlgorithms and Data Compression

Cited by 6

Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming

Rapoport, A., Stadtmauer, E., Melchiori, L., Wong, R., Davila, E., Binder-Scholl, G., Holdich, T., Vogl, D., Weiss, B., Finkelstein, J., et al. (2015) · Cancer Research

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 1